Interbiome Biologics Division cGMP bio-manufacturing of Investigative New Drugs (INDs) in a BSL-2 facility

    If you have an FDA license to use an "IND" in clinical trials, we have biologics manufacturing time slots available, to make the product you want to deliver





    Interbiome Drug Shortage Division

    cGMP manufacture of commercial drugs "abandoned" by pharma firms, yet still required for rare (orphan) & off-label patient needs, including oncology drugs of last resort (Small-molecule drugs as well as biologics)

    If there is an "abandoned" drug you wish to retain access to, we can arrange commercial manufacturing of the small-molecule or biologics product you need





    To others: The Entire Lifescience Industry is part of a larger Population Health Supply Chain

    Lagging throughput. Rife with Fallacies of Scale. Therapies cost too much (>$2Bil/drug), and take too long (~15 yr). The net process is plagued with uncertainties, so quality is expensive to manage.

    Only solution? Teamwork. Far richer feedback network, more interactions and more coordination. i.e., Biology-101 AND Industry-101